Biocon Ltd.

BSE: BIOCON532523ISIN INE376G01013

Healthcare
Pharmaceuticals
BSE 200

BSE listing

Share price

₹385.00+5.00 (+1.32%)

as of 18 Sep 2026

52W high: ₹447.00
52W low: ₹337.20
Off 52W high: -13.87%
1M return: -7.07%
3M return: -7.39%
6M return: +1.08%
1Y return: +4.52%
20D avg volume: 9,91,395
50 DMA: ₹416.07
200 DMA: ₹395.50

Key ratios Consolidated

Market cap: ₹62,743 Cr
Current price: ₹385.00
52W high / low: ₹447.00 / ₹337.20
Face value: ₹5.00
P/E: 150.68
P/B: —
EPS (TTM): ₹2.56
Book value / share: —
ROE: —
ROCE: 2.90%
Operating margin: —
Net margin: —
Debt / equity: 0.40
Net debt: ₹12,408 Cr
Interest cover: 1.45
Dividend yield: 0.13%
Dividend / share (TTM): ₹0.50
Payout: 19.53%
Cash conversion cycle: 114.3 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	4,336	4,517	4,173	4,296	3,942	4,417	3,821	3,590	3,433	3,917	3,954	3,462
	54.50	52.50	117.30	93.00	79.70	36.90	34.80	32.50	1,134	48.60	565.50	157.90
	4,249	4,241	4,065	4,205	3,925	3,988	3,718	3,550	3,454	3,635	3,708	3,358
	1,424	1,359	1,327	1,368	1,224	1,114	1,293	1,009	860.10	1,478	1,402	1,166
	381.90	222.60	167.90	135.00	837.10	83.50	85.50	49.10	408.50	0.10	33.30	372.00
	916.10	912.10	875.10	887.70	833.10	811.10	788.30	789.60	755.40	741.60	720.80	622.40
	213.20	231.50	209.90	272.20	276.70	212.40	223.40	225.60	236.00	227.00	266.70	247.70
	547.40	513.40	515.30	473.00	455.00	436.30	425.40	419.90	405.40	407.00	414.50	389.30
	1,105	1,185	1,125	1,025	954.80	1,055	956.10	977.20	—	1,004	1,076	975.20
	141.10	327.90	225.60	183.20	96.90	466.40	137.80	72.40	1,114	330.50	811.10	262.50
	-13.50	-80.40	-293.40	-11.90	0.00	20.40	18.10	26.00	32.00	-8.80	21.20	-24.00
	127.60	247.50	-67.80	171.30	96.90	486.80	155.90	98.40	1,146	321.70	832.30	238.50
	-9.20	48.90	-16.00	38.50	7.70	27.40	74.80	71.30	283.70	96.10	54.90	41.60
	136.80	198.60	-51.80	132.80	89.20	459.40	81.10	27.10	861.80	222.90	753.30	172.70
	0.87	0.79	1.08	0.66	0.26	2.88	0.21	-0.13	5.51	1.13	5.52	1.05
Key metrics
	888.20	992.40	657.40	916.50	828.60	1,136	804.70	743.90	1,787	955.70	1,514	875.50
	20.50%	22.00%	15.80%	21.30%	21.00%	25.70%	21.10%	20.70%	52.10%	24.40%	38.30%	25.30%
	3.20%	4.40%	-1.20%	3.10%	2.30%	10.40%	2.10%	0.80%	25.10%	5.70%	19.10%	5.00%
	—	1.00%	—	1.00%	—	1.60%	—	—	—	—	—	—
	10.00%	2.30%	9.20%	19.60%	14.80%	12.80%	-3.30%	3.70%	—	—	—	—
	53.40%	-56.80%	-163.90%	390.00%	-89.60%	106.10%	-89.20%	-84.30%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	17,321	16,927	15,262	14,756	11,174	8,184	7,106	6,367	5,514	4,130
	317.30	342.50	1,208	865.50	375.90	212.70	254.50	161.40	144.40	206.20
	16,761	16,419	14,680	14,000	10,195	7,096	6,226	5,381	4,639	3,747
	5,478	5,278	4,277	5,072	3,191	2,814	2,430	2,168	1,980	1,445
	907.40	1,363	626.60	682.70	626.10	161.10	68.40	85.40	126.80	232.80
	3,591	3,508	3,144	2,664	2,181	1,880	1,741	1,459	1,165	931.10
	926.80	990.30	897.40	974.40	419.00	67.60	57.70	64.90	70.90	61.50
	2,049	1,957	1,687	1,569	1,113	814.20	715.10	552.20	447.80	—
	4,440	4,273	3,754	3,979	3,211	—	—	—	1,329	901.80
	877.80	850.80	1,790	1,621	1,356	1,301	1,134	1,147	1,019	588.70
	-399.20	-402.90	96.50	-11.60	-291.40	-111.10	12.60	67.50	194.60	0.00
	478.60	447.90	1,887	1,609	1,064	1,190	1,147	1,215	1,214	588.70
	62.20	79.10	457.20	227.40	254.10	211.50	221.50	315.10	212.30	156.90
	416.40	368.80	1,429	1,298	643.00	771.60	846.20	870.90	1,003	431.80
	3.40	2.82	8.46	8.55	3.88	5.44	6.32	6.32	15.30	—
Key metrics
	3,454	3,395	4,471	4,153	2,596	2,072	1,920	1,832	1,733	650.20
	19.94%	20.10%	29.30%	28.10%	23.20%	25.30%	27.00%	28.80%	31.40%	15.70%
	2.40%	2.20%	9.40%	8.80%	5.80%	9.40%	11.90%	13.70%	18.20%	10.50%
	—	2.90%	6.30%	—	—	—	—	—	—	—
	—	10.90%	3.40%	32.10%	36.50%	15.20%	11.60%	15.50%	33.50%	—
	—	-74.20%	10.10%	101.80%	-16.70%	-8.80%	-2.80%	-13.10%	132.20%	—
	—	196.10	1,925	—	—	—	—	—	—	—
	—	5.41	2.84	—	—	—	—	—	—	—
	—	0.40	0.64	—	—	—	—	—	—	—
	—	12,408	14,528	—	—	—	—	—	—	—
	—	114.3	92.5	—	—	—	—	—	—	—
Balance sheet
	—	63,651	58,797	—	—	—	—	—	—	—
	—	17,180	16,286	—	—	—	—	—	—	—
	—	2,416	3,227	—	—	—	—	—	—	—
	—	5,987	5,488	—	—	—	—	—	—	—
	—	6,086	4,931	—	—	—	—	—	—	—
	—	887.10	0.00	—	—	—	—	—	—	—
	—	9,473	8,708	—	—	—	—	—	—	—
	—	6,772	6,549	—	—	—	—	—	—	—
	—	14,069	14,334	—	—	—	—	—	—	—
	—	14,825	17,756	—	—	—	—	—	—	—
	—	4,078	5,350	—	—	—	—	—	—	—
	—	10,746	12,405	—	—	—	—	—	—	—
	—	36,622	27,712	—	—	—	—	—	—	—
Cash flow
	—	1,994	4,061	—	—	—	—	—	—	—
	—	-2,082	-234.10	—	—	—	—	—	—	—
	—	-923.60	-1,854	—	—	—	—	—	—	—
	—	1,798	2,137	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	624.50	604.70	621.30	583.30	537.10	643.80	562.80	525.40	510.60	532.60	562.80	518.70
	64.80	49.80	74.80	133.80	61.30	62.70	64.20	73.50	41.90	38.90	48.50	69.60
	619.40	578.30	584.30	631.40	606.00	671.50	630.60	578.00	551.40	549.70	578.40	537.10
	261.90	246.10	287.60	320.70	288.00	322.40	276.80	263.00	223.20	217.70	264.40	291.50
	6.50	0.00	0.00	24.10	21.10	0.00	—	—	—	—	0.20	0.30
	133.10	93.60	121.70	126.20	125.70	124.30	131.90	125.40	119.70	116.80	117.60	112.50
	17.30	16.70	2.30	67.20	56.20	56.70	65.30	59.70	55.20	39.50	56.00	55.00
	38.40	36.20	34.00	33.80	33.30	33.00	33.80	30.50	30.50	29.80	30.90	30.60
	144.00	156.20	154.20	137.80	136.00	141.10	140.20	129.80	—	121.90	125.40	124.70
	69.90	76.20	111.80	85.70	-7.60	35.00	-3.60	20.90	1.10	21.80	32.90	51.20
	0.00	-18.80	-196.30	0.00	0.00	0.00	607.50	—	—	—	—	-5.20
	69.90	57.40	-84.50	85.70	-7.60	35.00	603.90	20.90	1.10	21.80	32.90	46.00
	17.70	6.40	-8.10	14.80	0.70	13.80	19.90	17.70	0.20	7.80	8.90	11.30
	52.20	51.00	-76.40	70.90	-8.30	21.20	584.00	3.20	0.90	14.00	24.00	34.70
	0.32	0.32	-0.57	0.55	-0.07	0.18	4.88	0.03	0.01	0.12	0.20	0.29
Key metrics
	125.60	110.30	-48.20	186.70	81.90	124.70	703.00	111.10	86.80	91.10	119.80	131.60
	20.10%	18.20%	-7.80%	32.00%	15.20%	19.40%	124.90%	21.10%	17.00%	17.10%	21.30%	25.40%
	8.40%	8.40%	-12.30%	12.20%	-1.50%	3.30%	103.80%	0.60%	0.20%	2.60%	4.30%	6.70%
	—	0.30%	—	0.90%	—	0.70%	—	—	—	—	—	—
	16.30%	-6.10%	10.40%	11.00%	5.20%	20.90%	0.00%	1.30%	—	—	—	—
	728.90%	140.60%	-113.10%	2,115.60%	-1,022.20%	51.40%	2,333.30%	-90.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	2,434	2,346	2,243	2,127	1,993	1,738	2,028	1,988	2,885	2,426
	323.20	319.70	242.30	193.00	271.40	187.20	150.20	201.70	117.50	124.70
	2,413	2,400	2,432	2,184	2,156	1,786	1,820	1,802	2,649	2,244
	1,116	1,142	1,085	1,033	978.90	912.30	760.70	858.20	1,278	958.70
	30.60	45.20	0.00	0.50	2.10	1.70	0.90	0.90	125.40	92.50
	474.60	467.20	501.30	452.30	433.80	367.70	390.20	344.80	510.30	408.60
	103.50	142.40	236.90	198.80	69.60	0.40	0.40	1.20	2.60	1.00
	142.40	137.30	127.80	121.10	116.90	108.20	103.50	98.00	147.10	136.10
	592.20	584.20	534.70	487.60	554.10	—	—	—	744.10	647.90
	343.60	266.10	53.40	135.80	108.40	139.70	358.80	388.50	353.40	305.80
	-215.10	-215.10	607.50	14.50	2,863	—	—	159.70	198.70	—
	128.50	51.00	660.90	150.30	2,971	139.70	358.80	548.20	552.10	305.80
	30.80	13.80	51.60	31.00	122.80	53.60	78.30	111.90	59.40	67.30
	97.70	37.20	609.30	119.30	2,848	86.10	280.50	440.90	492.70	238.50
	0.62	0.27	5.09	1.00	23.87	0.72	2.36	3.68	8.33	—
Key metrics
	374.40	330.70	1,026	470.20	3,158	248.30	462.70	647.40	701.80	442.90
	15.38%	14.10%	45.70%	22.10%	158.40%	14.30%	22.80%	32.60%	24.30%	18.30%
	4.01%	1.60%	27.20%	5.60%	142.90%	5.00%	13.80%	22.20%	17.10%	9.80%
	—	0.70%	6.50%	—	—	—	—	—	—	—
	—	4.60%	5.40%	6.70%	14.70%	-14.30%	2.00%	-31.10%	18.90%	—
	—	-93.90%	410.70%	-95.80%	3,208.20%	-69.30%	-36.40%	-10.50%	106.60%	—
	—	-463.10	303.70	—	—	—	—	—	—	—
	—	-4.84	1.02	—	—	—	—	—	—	—
	—	0.04	0.25	—	—	—	—	—	—	—
	—	1,059	2,622	—	—	—	—	—	—	—
	—	200.5	138.6	—	—	—	—	—	—	—
Balance sheet
	—	29,271	15,621	—	—	—	—	—	—	—
	—	2,288	2,170	—	—	—	—	—	—	—
	—	91.40	249.50	—	—	—	—	—	—	—
	—	1,003	829.40	—	—	—	—	—	—	—
	—	875.10	836.30	—	—	—	—	—	—	—
	—	100.60	120.00	—	—	—	—	—	—	—
	—	1,281	1,004	—	—	—	—	—	—	—
	—	588.80	814.40	—	—	—	—	—	—	—
	—	1,965	1,737	—	—	—	—	—	—	—
	—	1,150	2,871	—	—	—	—	—	—	—
	—	1,057	619.50	—	—	—	—	—	—	—
	—	93.50	2,252	—	—	—	—	—	—	—
	—	27,080	11,524	—	—	—	—	—	—	—
Cash flow
	—	-180.10	621.10	—	—	—	—	—	—	—
	—	-6,582	-989.00	—	—	—	—	—	—	—
	—	6,602	494.80	—	—	—	—	—	—	—
	—	283.00	317.40	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +5.59%
Sales CAGR 5Y: +2.96%
Sales CAGR 10Y: —
Profit CAGR 3Y: -76.45%
Profit CAGR 5Y: -33.24%
Profit CAGR 10Y: —
Sales YoY (TTM): +7.26%
Profit YoY (TTM): -83.72%

Consolidated

Sales CAGR 3Y: +14.85%
Sales CAGR 5Y: +18.96%
Sales CAGR 10Y: —
Profit CAGR 3Y: -16.91%
Profit CAGR 5Y: -15.30%
Profit CAGR 10Y: —
Sales YoY (TTM): +9.83%
Profit YoY (TTM): -36.60%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 44.68%

Holder	Type	Holding	Previous	Change
KIRAN MAZUMDAR SHAW	Promoter	29.73%	—	—
GLENTEC INTERNATIONAL	Promoter	14.56%	—	—
MAGNUM HYBRID LONG SHORT FUND	Public	8.75%	—	—
MYLAN INC.	Public	5.64%	—	—
LIFE INSURANCE CORPORATION OF INDIA	Public	3.73%	—	—
SERUM INSTITUTE LIFE SCIENCES PRIVATE LIMITED	Public	3.40%	—	—
ISIF EQUITY EX-TOP 100 LONG-SHORT FUND	Public	1.46%	—	—
KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK NIFTY MIDC	Public	1.29%	—	—
ACTIV PINE LLP	Public	1.08%	—	—
HDFC LIFE INSURANCE COMPANY LIMITED	Public	1.01%	—	—
RAVI RASENDRA MAZUMDAR	Promoter Group	0.33%	—	—
DEV MAZUMDAR	Promoter Group	0.06%	—	—
Carica Investment	Promoter Group	0.00%	—	—
Mazumdar Shaw Medical Foundation	Promoter Group	0.00%	—	—
BENEFICIAL HOLDINGS UNDER MGT-4	Public	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Communication regarding remittance of final dividend for the FY 2025-269 Sep 2026 · Company Update / General
Intimation of Schedule of Meetings with Analyst(s)/Institutional Investor(s)8 Sep 2026 · Company Update / Analyst / Investor Meet
Press Release8 Sep 2026 · Company Update / Press Release / Media Release
Intimation of Schedule of Meetings with Analyst(s)/Institutional Investor(s)31 Aug 2026 · Company Update / Analyst / Investor Meet
Communication regarding remittance of final dividend for the FY 2025-2628 Aug 2026 · Company Update / General
The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mylan Inc.26 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Company Statement25 Aug 2026 · Company Update / General
Company Statement18 Aug 2026 · Company Update / General
Investor Meet11 Aug 2026 · Company Update / Analyst / Investor Meet
Earning call Transcript for Q1 FY2711 Aug 2026 · Company Update / Earnings Call Transcript
Voting Results and Scrutinizer''s report8 Aug 2026 · AGM/EGM / AGM
Investor Meet7 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper Advertisement7 Aug 2026 · Company Update / Newspaper Publication
Resignation of Statutory auditors of material subsidiaries of the Company.6 Aug 2026 · Company Update / Resignation of Statutory Auditors
Change in Directorate6 Aug 2026 · Company Update / Change in Directorate
Completion of tenure of Statutory Auditors6 Aug 2026 · Company Update / General
Appointment of Statutory Auditors6 Aug 2026 · Company Update / Appointment of Statutory Auditor/s
Change in Directorate6 Aug 2026 · Company Update / Change in Directorate
Proceedings of the 48th AGM of the Company and the Chairperson''s speech.6 Aug 2026 · AGM/EGM / AGM
Audio and video recording of Q1 20276 Aug 2026 · Company Update / Analyst / Investor Meet
Investor Presentation6 Aug 2026 · Company Update / Investor Presentation
Monitoring Agency Report5 Aug 2026 · Company Update / Monitoring Agency Report
Press Release5 Aug 2026 · Company Update / Press Release / Media Release
Outcome of Board Meeting5 Aug 2026 · Board Meeting / Outcome of Board Meeting
Outcome of Board Meeting- Financial Results5 Aug 2026 · Result / Financial Results
Press Release3 Aug 2026 · Company Update / Press Release / Media Release
Commercial Launch of Product3 Aug 2026 · Company Update / General
Company Statement29 Jul 2026 · Company Update / General
Intimation of Earnings Conference call for Analysts and Investors28 Jul 2026 · Company Update / Analyst / Investor Meet
Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Intimation for the Board Meeting and ....28 Jul 2026 · Board Meeting / Board Meeting
Completion of tenure of Independent Director22 Jul 2026 · Company Update / Change in Directorate
Completion of tenure of Independent Director22 Jul 2026 · Company Update / Change in Directorate
Copy of Newspaper Advertisement16 Jul 2026 · Company Update / Newspaper Publication
Company Statement16 Jul 2026 · Company Update / General
Business Responsibility and Sustainability Reporting for the Financial Year 2025 - 2615 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Integrated Annual Report for the Financial Year 2025 - 2615 Jul 2026 · Others / Reg. 34 (1) Annual Report
48th Annual General Meeting for Financial Year 2025 - 26 to be held on Thursday, August 06, 202615 Jul 2026 · AGM/EGM / AGM
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mylan Inc.15 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Certificate under Reg 74(5) of SEBI (DP) Regulations13 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Press Release9 Jul 2026 · Company Update / Press Release / Media Release

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 0.5000	3 Jul 2026	3 Jul 2026	—
Final Dividend - Rs. - 0.5000	4 Jul 2025	4 Jul 2025	—
Final Dividend - Rs. - 0.5000	5 Jul 2024	5 Jul 2024	—

Board meetings

5 Aug 2026 Board Meeting - Financial Results